Celcuity Inc. (CELC) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Minneapolis, MN, United States. Le PDG actuel est Brian F. Sullivan.
CELC a date d'introduction en bourse 2017-09-20, 87 employés à temps plein, cotée sur le NASDAQ Capital Marke, une capitalisation boursière de $5.84B.
Celcuity Inc. is a clinical-stage biotechnology company headquartered in Minneapolis, Minnesota, focused on developing molecularly targeted cancer therapies for patients in the United States. The company's proprietary CELsignia diagnostic platform analyzes living tumor cells to identify the specific cellular abnormalities driving a patient's cancer and determines the most appropriate targeted treatment approach. Its lead drug candidate, Gedatolisib, selectively targets PI3K and mTOR pathways and is being evaluated for treating hormone receptor-positive, HER2-negative advanced or metastatic breast cancer under a license agreement with Pfizer. Celcuity is also advancing the CELsignia MP test, a laboratory-developed diagnostic that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor samples to guide therapeutic selection.
